Cabaletta Bio (CABA) Gains from Investment Securities (2024 - 2025)
Cabaletta Bio (CABA) posted quarterly Gains from Investment Securities of $79000.0 for Q4 2025, up 107.89% year-over-year from $38000.0 in Q4 2024, and down 7.06% quarter-over-quarter from $85000.0 in Q3 2025.
Powered by 
Analysis
Cabaletta Bio (CABA) Gains from Investment Securities (2024 - 2025) Analysis & Trends
Cabaletta Bio's Gains from Investment Securities history runs 2 years deep, the most recent figure standing at $79000.0 for Q4 2025.
- In Q4 2025, Gains from Investment Securities rose 107.89% year-over-year to $79000.0; the TTM figure through Dec 2025 stood at $225000.0 (up 492.11% YoY), while the FY2025 annual figure was $225000.0, up 492.11% from the prior year.
- Gains from Investment Securities for Q4 2025 stood at $79000.0, down from $85000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $85000.0 in Q3 2025, with the low at $29000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Cabaletta Bio | 522.26 Mn | 522.26 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 79,000.00 |
| Sep 30, 2025 | 85,000.00 |
| Jun 30, 2025 | 32,000.00 |
| Mar 31, 2025 | 29,000.00 |
| Dec 31, 2024 | 38,000.00 |